AriBio Co., Ltd. is a South Korean biotechnology company headquartered in Seoul, South Korea, dedicated to developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. Founded in 2015, AriBio focuses on innovative approaches targeting protein aggregation and neuroprotection[@aribio].
The company has advanced its lead candidate AR1001 through clinical development and is building a pipeline of next-generation therapies for Alzheimer's disease.
Pipeline Overview
| Program | Target/Mechanism | Indication | Stage | Status | |---------|-----------------|------------|-------|--------| | AR1001 | PDE5 inhibitor | Alzheimer's disease | Phase 2/3 | Active | | AR1002 | Tau aggregation inhibitor | Alzheimer's disease | Preclinical | Research | | AR1003 | Anti-amyloid antibody | Alzheimer's disease | Discovery | Research |
Lead Program: AR1001
Mechanism of Action
AR1001 is a phosphodiesterase 5 (PDE5) inhibitor being developed for Alzheimer's disease. PDE5 inhibition is believed to provide neuroprotective effects through multiple pathways[@pde2024]:
Synaptic protection: Enhanced synaptic plasticity and function
Tau phosphorylation modulation: Effects on tau pathology
Clinical Development
...
Overview
AriBio Co., Ltd. is a South Korean biotechnology company headquartered in Seoul, South Korea, dedicated to developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. Founded in 2015, AriBio focuses on innovative approaches targeting protein aggregation and neuroprotection[@aribio].
The company has advanced its lead candidate AR1001 through clinical development and is building a pipeline of next-generation therapies for Alzheimer's disease.
Pipeline Overview
| Program | Target/Mechanism | Indication | Stage | Status | |---------|-----------------|------------|-------|--------| | AR1001 | PDE5 inhibitor | Alzheimer's disease | Phase 2/3 | Active | | AR1002 | Tau aggregation inhibitor | Alzheimer's disease | Preclinical | Research | | AR1003 | Anti-amyloid antibody | Alzheimer's disease | Discovery | Research |
Lead Program: AR1001
Mechanism of Action
AR1001 is a phosphodiesterase 5 (PDE5) inhibitor being developed for Alzheimer's disease. PDE5 inhibition is believed to provide neuroprotective effects through multiple pathways[@pde2024]:
Synaptic protection: Enhanced synaptic plasticity and function
Tau phosphorylation modulation: Effects on tau pathology
Clinical Development
Phase 2/3 Trial (2024-2025):
Randomized, double-blind, placebo-controlled study
Primary endpoints: Cognitive function (ADAS-Cog13), functional capacity (ADCS-ADL)
Enrollment: Patients with mild-to-moderate Alzheimer's disease
Results expected: 2025-2026
Phase 1 Studies:
Completed single and multiple ascending dose studies
Demonstrated favorable safety and tolerability
Good brain penetration achieved
Clinical Rationale
The PDE5 target in Alzheimer's disease is supported by multiple lines of evidence:
PDE5 expression is elevated in AD brains
cGMP signaling is reduced in AD
PDE5 inhibition improves memory in animal models
Crosses the [blood-brain barrier](/entities/blood-brain-barrier) effectively
AR1002: Tau Aggregation Inhibitor
Program Overview
AR1002 targets [tau protein](/proteins/tau) aggregation, a key pathological feature of Alzheimer's disease. This program is in preclinical development[@tau2023].
Mechanism:
Inhibits tau protein aggregation
Promotes tau clearance
May reduce neurofibrillary tangle formation
Status:
Lead optimization completed
IND-enabling studies planned
Science and Research
Alzheimer's Disease Focus
AriBio's approach to Alzheimer's disease addresses multiple pathological hallmarks:
Amyloid Pathology: Through potential anti-amyloid programs
Tau Pathology: Via AR1002 tau aggregation inhibitor